Active Portfolio
iTeos Therapeutics is developing next generation immunotherapies targeting inflamed and non-inflamed tumors. Lead programs include a best-in-class adenosine A2A receptor antagonist for cancer immunotherapy and a highly differentiated anti-TIGIT mAb.
Includes active MPM and BioImpact Capital portfolio companies, that were private companies at the date of initial investment in funds launched on or after 2010. Excludes passive investments and investments that did not progress scientifically and have been written off. Notwithstanding the foregoing, certain private companies are not illustrated (1) because of confidentiality restrictions or arrangements or (2) because, to the best of MPM’s knowledge, such company does not have a logo or active website. References, either general or specific, to securities and/or issuers are for illustrative purposes only and are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. MPM makes no representations, and it should not be assumed, that past investment selection is necessarily indicative of future investment selection or performance. Contact us at info@mpmcapital.com to request the most up to date information.